公开(公告)号：EP3172788A1

公开(公告)日：2017-05-31

申请号：EP15745070.1

申请日：2015-07-21

申请人： LG Fuel Cell Systems Inc. ,  University of South Carolina

发明人： JUNG, Hwa Young ,  XING, Zhengliang ,  LIU, Zhien ,  GOETTLER, Richard W. ,  ZHOU, Xiao-Dong ,  DOGDIBEGOVIC, Emir

IPC分类号： H01M8/00 ,  H01M4/90 ,  B01J23/00 ,  C04B35/00 ,  H01M8/12 ,  H01M8/02

CPC分类号： H01M4/9033 ,  C04B35/01 ,  C04B2235/3213 ,  C04B2235/3224 ,  C04B2235/3227 ,  C04B2235/3241 ,  C04B2235/3262 ,  C04B2235/3274 ,  C04B2235/3275 ,  C04B2235/3279 ,  C04B2235/3281 ,  C04B2235/3284 ,  C04B2235/76 ,  C04B2235/768 ,  C04B2235/80 ,  H01M8/004 ,  H01M8/006 ,  H01M8/0217 ,  H01M8/0236 ,  H01M8/1231 ,  H01M8/1246 ,  H01M2008/1293 ,  H01M2300/0071 ,  H01M2300/0074 ,  Y02E60/525 ,  Y02P70/56

摘要： In some examples, a fuel cell including an anode; electrolyte; and cathode separated from the anode by the electrolyte, wherein the cathode includes a Pr-nickelate based material with (Pr1-xAx)n+1(Ni1-yBy)nO3n+1+δ as a general formula, where n is 1 as an integer, A is an A-site dopant including of a metal of a group formed by one or more lanthanides, and B is a B-site dopant including of a metal of a group formed by one or more transition metals, wherein the A and B-site dopants are provided such that there is an increase in phase-stability and reduction in degradation of the Pr-nickelate based material, and A is at least one metal cation of lanthanides, La, Nd, Sm, or Gd, B is at least one metal cation of transition metals, Cu, Co, Mn, Zn, or Cr, where: 0

摘要翻译： 在一些示例中，燃料电池包括阳极; 电解质; 和通过电解质与阳极隔开的阴极，其中阴极包括具有（Pr1-xAx）n + 1（Ni1-yBy）nO3n + 1 +δ作为通式的Pr-镍酸盐基材料，其中n是1，作为 整数，A是包含由一种或多种镧系元素形成的基团的金属的A位掺杂剂，B是包含由一种或多种过渡金属形成的基团的金属的B位掺杂剂，其中A和 提供B位掺杂剂使得基于镍酸盐的材料的相稳定性增加和降解降低，并且A是镧系元素La，Nd，Sm或Gd中的至少一种金属阳离子，B是 至少一种过渡金属Cu，Co，Mn，Zn或Cr的金属阳离子，其中：0

公开(公告)号：EP2430651B1

公开(公告)日：2016-04-27

申请号：EP10711798.8

申请日：2010-03-09

申请人： Cree, Inc. ,  University of South Carolina

发明人： ZHANG, Qingchun ,  AGARWAL, Anant, K. ,  SUDARSHAN, Tangali, S. ,  BOLOTNIKOV, Alexander

IPC分类号： H01L21/266 ,  H01L21/223 ,  H01L29/06 ,  H01L29/861 ,  H01L29/872 ,  H01L29/16

CPC分类号： H01L29/1608 ,  H01L21/0465 ,  H01L21/223 ,  H01L29/0615 ,  H01L29/0657 ,  H01L29/0661 ,  H01L29/36 ,  H01L29/8613 ,  H01L29/872

公开(公告)号：EP2914266A1

公开(公告)日：2015-09-09

申请号：EP13795625.6

申请日：2013-11-01

申请人： University of South Carolina

发明人： RONINSON, Igor ,  CHEN, Mengqian

IPC分类号： A61K31/517 ,  A61K31/5377 ,  C07D239/94

CPC分类号： A61K31/517 ,  A61K31/5377

摘要： The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of CDK8 and CDK19. In some embodiments the inhibitor inhibits CDK19. In some embodiments, the inhibitor inhibits CDK8 at a Kd of lower than 200 nM and/or inhibits CDK19 at a Kd of lower than 100 nM. In some embodiments, the prostate cancer is androgen independent. In some embodiments, the prostate cancer is androgen independent due to one or more of androgen receptor gene amplification, androgen receptor gene mutation, ligand-independent transactivation of androgen receptor and activation of intracellular androgen synthesis. In some embodiments, the inhibitor inhibits increased activity of NF-κB. In some embodiments, the inhibitor does not inhibit increased basal levels of NF-κB. In some embodiments, inhibition of one or more genes by AR is not inhibited.

摘要翻译： 本发明提供了一种用于治疗受试者中前列腺癌的方法，包括给予受试者有效量的一种或多种CDK8和CDK19的选择性抑制剂。 在一些实施方案中，抑制剂抑制CDK19。 在一些实施方案中，抑制剂以低于200nM的Kd抑制CDK8和/或以低于100nM的Kd抑制CDK19。 在一些实施方案中，前列腺癌是与雄激素无关的。 在一些实施方案中，由于雄激素受体基因扩增，雄激素受体基因突变，雄激素受体的配体非依赖性反式激活和细胞内雄激素合成的激活中的一种或多种，​​前列腺癌是独立的。 在一些实施方案中，抑制剂抑制NF-κB的活性增加。 在一些实施方案中，抑制剂不抑制NF-κB的增加的基础水平。 在一些实施方案中，AR抑制一个或多个基因不被抑制。

公开(公告)号：EP2289535A2

公开(公告)日：2011-03-02

申请号：EP10185372.9

申请日：2005-12-20

申请人： MEDICAL UNIVERSITY OF SOUTH CAROLINA

发明人： Gourdie, Robert ,  Ghatnekar, Gautam ,  Jourdan, Jane

IPC分类号： A61K38/17 ,  C07K11/00 ,  C07K14/705

CPC分类号： A61K38/177 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61K38/1709 ,  A61K38/1767 ,  A61K45/06 ,  A61L31/08 ,  A61L2430/34 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/43581 ,  C07K14/47 ,  C07K14/705 ,  C07K2319/01 ,  C07K2319/10

摘要： Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

摘要翻译： 本文提供了用于促进受试者组织损伤后的伤口愈合和组织再生的组合物和方法。

公开(公告)号：EP2070583A3

公开(公告)日：2009-11-04

申请号：EP09003669.0

申请日：2003-08-01

申请人： UNIVERSITY OF SOUTH CAROLINA

发明人： Davis, Thomas, A.

IPC分类号： B01D61/02 ,  B01D61/58 ,  B01D61/44 ,  B01D61/52 ,  C02F1/469

CPC分类号： C02F1/441 ,  B01D61/025 ,  B01D61/027 ,  B01D61/422 ,  B01D61/44 ,  B01D61/52 ,  B01D61/58 ,  C02F1/048 ,  C02F1/442 ,  C02F1/444 ,  C02F1/469 ,  C02F1/4693 ,  C02F9/00 ,  C02F2103/08 ,  C02F2201/46115 ,  Y02A20/128 ,  Y02A20/131 ,  Y02A20/134 ,  Y02W10/37

摘要： Sodium chloride and purified water are recovered by treating salt water that contains sodium chloride with an integrated reverse osmosis and electrodialysis system, which includes an efficiency-enhancing feature that is one or more of the following: the use of univalent anion and univalent cation selective membranes in the electrodialysis unit; the addition of a nanofiltration unit to process the diluate from the electrodialysis unit; or operation of the electrodialysis unit at an elevated pressure. Magnesium and bromine can optionally be produced when the salt water contains these materials.

摘要翻译： 氯化钠和纯净水通过处理海水那样回收的含有氯化钠与集成反渗透和电渗析系统，其中包括对提高效率的功能所做的是一个或多个以下的：利用价阴离子和一价阳离子选择性膜 在电渗析装置; 加入纳米过滤单元的处理来自所述电渗析单元稀液; 或在升高的压力下的电渗析装置的手术。 镁和溴可制备可选地，当盐水包含论文材料。

公开(公告)号：EP1004042B1

公开(公告)日：2009-08-26

申请号：EP98936831.1

申请日：1998-07-09

申请人： UNIVERSITY OF SOUTH CAROLINA

发明人： MYRICK, Michael, L. ,  NELSON, Mathew, P. ,  BOOKSH, Karl, S.

IPC分类号： G02B1/00 ,  G01J3/12 ,  G01J3/28

CPC分类号： G01N21/274 ,  G01J3/28 ,  G01N21/31 ,  G01N2021/3196

摘要： An optical analysis system includes an optical filter mechanism disposed to receive light from a light source and configured to optically compress data carried by the light into at least one orthogonal component of the light. A detector mechanism in operative communication with the optical filter mechanism measures a property of the at least one orthogonal component to measure the data.

公开(公告)号：EP1955046A1

公开(公告)日：2008-08-13

申请号：EP06738057.6

申请日：2006-03-10

申请人： University of South Carolina

发明人： MYRICK, Michael, L. ,  FREESE, Robert, P. ,  PRIORE, Ryan, J. ,  BLACKBURN, John, C. ,  JAMES, Jonathan, H. ,  PERKINS, David L.

IPC分类号： G01N21/31 ,  G01N21/85

CPC分类号： G01N21/4738 ,  G01N21/31 ,  G01N21/9508

摘要： A method of high-speed processing and monitoring of a product, such as a pharmaceutical powder or tablet, comprises: moving the product (C) past an inspection station; illuminating at least a portion of the product with light; spectrally filtering a first portion of light carrying invormation about the product, o.g., transmitted or reflected light, by passing said first portion through at least one multivariate optical element (148) and detecting said filtered light with a first detector (152), - detecting a deflected second portion of said light with a second detector (156); and determining at least one selected property of the product based on the detector outputs.

公开(公告)号：EP1825269A2

公开(公告)日：2007-08-29

申请号：EP05853792.9

申请日：2005-12-13

申请人： UNIVERSITY OF SOUTH CAROLINA

发明人： MURPHY, Catherine J., University of S. Carolina ,  SAU, Tapan, K., c/o Punjab University ,  ORENDORFF, C.J., Biomolecular Interfaces & Systems ,  GOLE, Anand M., Inst. Bioeng. & Nanotechnology

IPC分类号： G01N33/553

CPC分类号： G01N33/553 ,  B82Y30/00 ,  G01N21/658 ,  G01N33/54373 ,  G01N2610/00 ,  Y10S436/805 ,  Y10T428/25 ,  Y10T428/2991

摘要： In one aspect, the invention relates to methods for enhancing a Raman signal comprising the steps of providing a sample comprising a metal surface, an analyte adhered to the surface, and a metallic nanoparticle coupled to the surface, wherein the nanoparticle has a plasmon resonance band; exposing the sample to incident energy of an excitation wavelength; and detecting the Raman signal of the analyte. In a further aspect, the invention relates to a composition comprising a metal surface, a functionalized self-assembled monolayer adhered to the surface, wherein the self-assembled monolayer comprises an analyte, and a cetyltrialkylammonium halide-capped metallic nanoparticle coupled to the surface. In a further aspect, the invention relates to a cetyltrimethylammonium bromide-capped gold nanoparticle and a method for preparing same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：EP1809408A2

公开(公告)日：2007-07-25

申请号：EP05796110.4

申请日：2005-09-13

申请人： UNIVERSITY OF SOUTH CAROLINA

发明人： DAVIS, Thomas, A.

IPC分类号： B01D61/02 ,  B01D61/42

CPC分类号： B01D61/44 ,  B01D61/022 ,  B01D61/025 ,  B01D61/027 ,  B01D61/422 ,  B01D61/445 ,  B01D61/48 ,  B01D61/52 ,  B01D61/58 ,  C01D3/06 ,  C01F11/46 ,  C02F1/441 ,  C02F1/469 ,  C02F1/4693 ,  C02F1/5236 ,  C02F5/00 ,  C02F2101/103 ,  C02F2103/08 ,  Y02A20/131 ,  Y02A20/134

摘要： A process and system for purifying water is disclosed. For example, in one embodiment, the process may be used to remove a divalent salt, such as calcium sulfate, from a water source in order to prevent the divalent salt from precipitating during the process. The water source, for instance, may be fed to an ion separating device, such as an electrodialysis device. In the electrodialysis device, an ion exchange takes place between the divalent salt and another salt, such as a monovalent salt to produce two concentrated salt streams that contain salts having greater solubility in water than the divalent salt. In one embodiment, the two salt streams that are produced may then be combined to precipitate the divalent salt in a controlled manner. During the process, various other components contained within the water feed stream may also be removed from the stream and converted into useful products. In one particular embodiment, the process is configured to receive a byproduct stream from a reverse osmosis process.

公开(公告)号：EP1702983A3

公开(公告)日：2007-01-10

申请号：EP06001413.1

申请日：2001-04-13

申请人： MEDICAL UNIVERSITY OF SOUTH CAROLINA ,  THE PENN STATE RESEARCH FOUNDATION

发明人： Norris, James, S. ,  Clawson, Gary, A. ,  Westwater, Caroline ,  Schofield, David ,  Schmidt, Michael, G. ,  Hoel, Brian ,  Dolan, Joseph ,  Pan, Wei-Hua

IPC分类号： C12N15/11 ,  C12N15/74

CPC分类号： C12N15/113 ,  A61K38/00 ,  A61K48/00 ,  C12N15/1131 ,  C12N15/74 ,  C12N2310/111 ,  C12N2310/12 ,  C12N2310/317

摘要： The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention has important implications in the eradication of drug-resistant pathogens (such as antibiotic resistant bacteria) and drug-resistant diseased cells (such as drug-resistant cancer cells).